Medicament for the treatment of viral skin and tumour diseases

Abstract

The invention relates to a medicament containing a compound of general formula (I), where R1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C11-C21 alkyl, alkylene or alkinyl group, preferably a C11-C15 alkyl, alkylene or alkinyl group, particularly a C11-C13 alkyl, alkylene or alkinyl group, most preferably a C13 alkyl group, R2=independently, a straight or branched C1-C8 alkyl, alkylene or alkinyl group, preferably a C1-C6 alkyl, alkylene or alkinyl group, in particular a C2-C4 alkyl, alkylene or alkinyl group, most preferably a C3 alkyl group, a —[CH2—(CH2)m—O]nH group with n=1 to 10, preferably n=1 to 5, to m=1 to 5, preferably m=1 to 3, a —CH2—[CH—(OH)]p [CH2—R3]-group, where R3=independently H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof.

1 . A pharmaceutical composition comprising:
 (i) a compound having the formula
   A-B   (I),
 
 wherein A is a radical having the formula 
   
       
         
           
           
               
               
           
         
         
           and wherein B is a radical having the formula
   —O—R 2    (III),
 
 
           and wherein R 1  is, independent of each other, an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C 13 -C 21  alkyl, alkylene, or alkynyl radical, and R 2  is, independent of each other, an unbranched or branched C 1 -C 8  alkyl, alkylene, or alkynyl radical; and 
         
         (ii) a mixture of catechols comprising 4-15% (w/w) of (−)-epicatechol, 2-20% (w/w) of (−)-epicatechol gallate, 3-15% (w/w) of (−)-epigallocatechol, 40-75% (w/w) of (−)-epigallocatechol gallate, 0.1-1% (w/w) of (+)-gallocatechol, and 1-10% (w/w) of (−)-gallocatechol gallate; and 
         wherein the pharmaceutical comprises at least 5-50% (w/w) of the compound of formula (I). 
       
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutical composition comprises 1-30% (w/w) of said mixture of catechols and at least 10-50% (w/w) of said compound of formula (I). 
     
     
         3 . The pharmaceutical composition of  claim 2 , wherein said pharmaceutical composition comprises 2-20% (w/w) of said mixture of catechols. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein said pharmaceutical composition comprises 15-18% (w/w) of said mixture of catechols. 
     
     
         5 . The pharmaceutical composition of  claim 2 , wherein said pharmaceutical composition comprises at least 25-50% (w/w) of said compound of formula (I). 
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein said pharmaceutical composition comprises at least 35-50% (w/w) of said compound of formula (I). 
     
     
         7 . The pharmaceutical composition of  claim 1 , wherein said mixture of catechols comprises 5-7% (w/w) of said (−)-epicatechol gallate. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein said mixture of catechols comprises 0.1-0.6% (w/w) of said (+)-gallocatechol. 
     
     
         9 . The pharmaceutical composition of  claim 1 , wherein said mixture of catechols comprises 1-5% (w/w) of said (−)-gallocatechol gallate. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein said mixture of catechols comprises 10.8% (w/w) of (−)-epicatechol, 6.5% (w/w) of (−)-epicatechol gallate, 9.2% (w/w) of (−)-epigallocatechol, 54.8% (w/w) of (−)-epigallocatechol gallate, and/or 4.0% (w/w) of (−)-gallocatechol gallate. 
     
     
         11 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutical composition comprises at least 10-50% (w/w) of said compound of formula (I). 
     
     
         12 . The pharmaceutical composition of  claim 11 , wherein said pharmaceutical composition comprises at least 25-50% (w/w) of said compound of formula (I). 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein said pharmaceutical composition comprises at least 35-50% (w/w) of said compound of formula (I). 
     
     
         14 . The pharmaceutical composition of  claim 1 , wherein said catechols are isolated from a tea extract. 
     
     
         15 . The pharmaceutical composition of  claim 1 , wherein one or more additional pharmaceutical compound(s) is/are administered simultaneously or separately. 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein said one or more additional pharmaceutical compound(s) is/are amphiphilic. 
     
     
         17 . The pharmaceutical composition of  claim 1 , further comprising additives and/or auxiliary substances. 
     
     
         18 . The pharmaceutical composition of  claim 17 , wherein said additives and/or auxiliary substances are hydrophobic and are selected from the group consisting of petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate, and propylene glycol monopalmitostearate. 
     
     
         19 . A pharmaceutical composition comprising 35% (w/w) of a compound having the formula
   A-B   (I),
   wherein A is a radical having the formula   
       
         
           
           
               
               
           
         
         and wherein B is a radical having the formula
   —O—R 2    (III),
 
 
         and wherein R 1  is, independent of each other, an unbranched or branched, saturated, singly or multiply unsaturated, optionally substituted C 13 -C 21  alkyl, alkylene, or alkynyl radical, and R 2  is, independent of each other, an unbranched or branched C 1 -C 8  alkyl, alkylene, or alkynyl radical; 
         and wherein said pharmaceutical composition further comprises 15% (w/w) of a mixture of catechols comprising 4-15% (w/w) of (−)-epicatechol, 2-20% (w/w) of (−)-epicatechol gallate, 3-15% (w/w) of (−)-epigallocatechol, 40-75% (w/w) of (−)-epigallocatechol gallate, 0.1-1% (w/w) of (+)-gallocatechol, 1-10% (w/w) of (−)-gallocatechol gallate, 24.5% (w/w) of petroleum jelly, 20% (w/w) of wax, 5% (w/w) of propylene glycol monostearate or propylene glycol monopalmitostearate, and 0.5% (w/w) of oleyl alcohol. 
       
     
     
         20 . A method of treating a papilloma virus-induced skin disease or benign tumor disease in a patient, said method comprising administering to a patient a pharmaceutical composition of  claim 1 . 
     
     
         21 . The method of  claim 20 , wherein said papilloma virus-induced skin disease or benign tumor disease is caused by HPV 1, 2, 3, 4, 5, 6, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19-29, 31, 32, 34, 36-38, 46-50, 56, or 58. 
     
     
         22 . The method of  claim 20 , wherein said papilloma virus-induced skin diseases are warts or genital warts and the papilloma virus-induced benign tumors are of the skin and/or mucosa. 
     
     
         23 . The method of  claim 22 , wherein said papilloma virus-induced benign tumors of the skin and/or mucosa are verrucae plantares, verrucae vulgares, verrucae planae juveniles, epidermodysplasia verruciformis,  Condylomata acuminata, Condylomata plana , bowenoid papulosis, papillomas on the larynx and oral mucosa, or focal epithelial hyperplasia. 
     
     
         24 . The method of  claim 20 , wherein said pharmaceutical composition is applied topically. 
     
     
         25 . The method of  claim 24 , wherein said pharmaceutical composition is applied genitally or vaginally.